#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Gut Microbiota in RA and OA
1-1	0-2	3.	_	_	_	_
1-2	3-6	Gut	person|abstract[2]	new|new[2]	_	_
1-3	7-17	Microbiota	abstract[2]	new[2]	_	_
1-4	18-20	in	abstract[2]	new[2]	_	_
1-5	21-23	RA	abstract[2]|organization	new[2]|new	coref	2-18
1-6	24-27	and	abstract[2]	new[2]	_	_
1-7	28-30	OA	abstract[2]|abstract	new[2]|new	_	_

#Text=The hypothesis that not only oral but also intestinal microbiota can be associated with the development of RA is supported by many data .
2-1	31-34	The	abstract[5]	new[5]	_	_
2-2	35-45	hypothesis	abstract[5]	new[5]	_	_
2-3	46-50	that	abstract[5]	new[5]	_	_
2-4	51-54	not	abstract[5]	new[5]	_	_
2-5	55-59	only	abstract[5]|substance[6]	new[5]|new[6]	_	_
2-6	60-64	oral	abstract[5]|substance[6]	new[5]|new[6]	_	_
2-7	65-68	but	abstract[5]|substance[6]	new[5]|new[6]	_	_
2-8	69-73	also	abstract[5]|substance[6]	new[5]|new[6]	_	_
2-9	74-84	intestinal	abstract[5]|substance[6]	new[5]|new[6]	_	_
2-10	85-95	microbiota	abstract[5]|substance[6]	new[5]|new[6]	_	_
2-11	96-99	can	abstract[5]	new[5]	_	_
2-12	100-102	be	abstract[5]	new[5]	_	_
2-13	103-113	associated	abstract[5]	new[5]	_	_
2-14	114-118	with	abstract[5]	new[5]	_	_
2-15	119-122	the	abstract[5]|event[7]	new[5]|new[7]	_	_
2-16	123-134	development	abstract[5]|event[7]	new[5]|new[7]	_	_
2-17	135-137	of	abstract[5]|event[7]	new[5]|new[7]	_	_
2-18	138-140	RA	abstract[5]|event[7]|organization	new[5]|new[7]|giv	coref	3-28
2-19	141-143	is	_	_	_	_
2-20	144-153	supported	_	_	_	_
2-21	154-156	by	_	_	_	_
2-22	157-161	many	abstract[9]	new[9]	_	_
2-23	162-166	data	abstract[9]	new[9]	_	_
2-24	167-168	.	_	_	_	_

#Text=Zhang et al. published a case-control metagenome-wide association study ( MGWAS ) of the fecal , dental and salivary microbiomes of a cohort of treatment-naive and treated RA patients .
3-1	169-174	Zhang	person	new	_	_
3-2	175-177	et	_	_	_	_
3-3	178-181	al.	_	_	_	_
3-4	182-191	published	_	_	_	_
3-5	192-193	a	abstract[12]	new[12]	appos	3-11[0_12]
3-6	194-206	case-control	abstract[12]	new[12]	_	_
3-7	207-222	metagenome-wide	abstract[12]	new[12]	_	_
3-8	223-234	association	organization|abstract[12]	new|new[12]	_	_
3-9	235-240	study	abstract[12]	new[12]	_	_
3-10	241-242	(	_	_	_	_
3-11	243-248	MGWAS	abstract	giv	coref	5-2[23_0]
3-12	249-250	)	_	_	_	_
3-13	251-253	of	_	_	_	_
3-14	254-257	the	substance[14]	new[14]	_	_
3-15	258-263	fecal	substance[14]	new[14]	_	_
3-16	264-265	,	substance[14]	new[14]	_	_
3-17	266-272	dental	substance[14]	new[14]	_	_
3-18	273-276	and	substance[14]	new[14]	_	_
3-19	277-285	salivary	substance[14]	new[14]	_	_
3-20	286-297	microbiomes	substance[14]	new[14]	_	_
3-21	298-300	of	substance[14]	new[14]	_	_
3-22	301-302	a	substance[14]|person[15]	new[14]|new[15]	_	_
3-23	303-309	cohort	substance[14]|person[15]	new[14]|new[15]	_	_
3-24	310-312	of	substance[14]|person[15]	new[14]|new[15]	_	_
3-25	313-328	treatment-naive	substance[14]|person[15]|person[17]	new[14]|new[15]|new[17]	ana	4-1[0_17]
3-26	329-332	and	substance[14]|person[15]|person[17]	new[14]|new[15]|new[17]	_	_
3-27	333-340	treated	substance[14]|person[15]|person[17]	new[14]|new[15]|new[17]	_	_
3-28	341-343	RA	substance[14]|person[15]|organization|person[17]	new[14]|new[15]|giv|new[17]	coref	5-12
3-29	344-352	patients	substance[14]|person[15]|person[17]	new[14]|new[15]|new[17]	_	_
3-30	353-354	.	_	_	_	_

#Text=They found that the RA-associated microbiome deviated significantly from healthy controls in all sites .
4-1	355-359	They	person	giv	coref	6-1[34_0]
4-2	360-365	found	_	_	_	_
4-3	366-370	that	_	_	_	_
4-4	371-374	the	abstract[20]	new[20]	coref	8-1[51_20]
4-5	375-388	RA-associated	abstract|abstract[20]	new|new[20]	_	_
4-6	389-399	microbiome	abstract[20]	new[20]	_	_
4-7	400-408	deviated	_	_	_	_
4-8	409-422	significantly	_	_	_	_
4-9	423-427	from	_	_	_	_
4-10	428-435	healthy	abstract[21]	new[21]	_	_
4-11	436-444	controls	abstract[21]	new[21]	_	_
4-12	445-447	in	_	_	_	_
4-13	448-451	all	place[22]	new[22]	coref	5-30[33_22]
4-14	452-457	sites	place[22]	new[22]	_	_
4-15	458-459	.	_	_	_	_

#Text=In this study , Haemophilus spp. was depleted in individuals with RA at the fecal and oral levels , whereas Lactobacillus salivarius was over-represented in individuals with RA at both microbiota sites .
5-1	460-462	In	_	_	_	_
5-2	463-467	this	abstract[23]	giv[23]	_	_
5-3	468-473	study	abstract[23]	giv[23]	_	_
5-4	474-475	,	_	_	_	_
5-5	476-487	Haemophilus	abstract	new	_	_
5-6	488-492	spp.	animal	new	_	_
5-7	493-496	was	_	_	_	_
5-8	497-505	depleted	_	_	_	_
5-9	506-508	in	_	_	_	_
5-10	509-520	individuals	person[26]	new[26]	coref	5-26[30_26]
5-11	521-525	with	person[26]	new[26]	_	_
5-12	526-528	RA	person[26]|organization	new[26]|giv	coref	5-28
5-13	529-531	at	_	_	_	_
5-14	532-535	the	abstract[28]	new[28]	_	_
5-15	536-541	fecal	abstract[28]	new[28]	_	_
5-16	542-545	and	abstract[28]	new[28]	_	_
5-17	546-550	oral	abstract[28]	new[28]	_	_
5-18	551-557	levels	abstract[28]	new[28]	_	_
5-19	558-559	,	_	_	_	_
5-20	560-567	whereas	_	_	_	_
5-21	568-581	Lactobacillus	abstract[29]	new[29]	_	_
5-22	582-592	salivarius	abstract[29]	new[29]	_	_
5-23	593-596	was	_	_	_	_
5-24	597-613	over-represented	_	_	_	_
5-25	614-616	in	_	_	_	_
5-26	617-628	individuals	person[30]	giv[30]	_	_
5-27	629-633	with	person[30]	giv[30]	_	_
5-28	634-636	RA	person[30]|organization	giv[30]|giv	ana	6-10
5-29	637-639	at	_	_	_	_
5-30	640-644	both	place[33]	giv[33]	_	_
5-31	645-655	microbiota	abstract|place[33]	new|giv[33]	coref	7-3[40_0]
5-32	656-661	sites	place[33]	giv[33]	_	_
5-33	662-663	.	_	_	_	_

#Text=Older patients often manifest more severe diseases , and this appears connected to age-related gut dysbiosis .
6-1	664-669	Older	person[34]	giv[34]	coref	10-38[85_34]
6-2	670-678	patients	person[34]	giv[34]	_	_
6-3	679-684	often	_	_	_	_
6-4	685-693	manifest	_	_	_	_
6-5	694-698	more	abstract[35]	new[35]	coref	8-13[54_35]
6-6	699-705	severe	abstract[35]	new[35]	_	_
6-7	706-714	diseases	abstract[35]	new[35]	_	_
6-8	715-716	,	_	_	_	_
6-9	717-720	and	_	_	_	_
6-10	721-725	this	organization	giv	coref	9-28
6-11	726-733	appears	_	_	_	_
6-12	734-743	connected	_	_	_	_
6-13	744-746	to	_	_	_	_
6-14	747-758	age-related	abstract[38]	new[38]	_	_
6-15	759-762	gut	abstract|abstract[38]	new|new[38]	coref	11-8
6-16	763-772	dysbiosis	abstract[38]	new[38]	_	_
6-17	773-774	.	_	_	_	_

#Text=Alterations in the microbiota provide plausible candidate mechanisms for driving both inflammation and altering the immune response and host metabolism , which in turn may modulate the development of musculoskeletal problems ( see the Prevotella copri case below ) .
7-1	775-786	Alterations	abstract[39]	new[39]	coref	20-22[174_39]
7-2	787-789	in	abstract[39]	new[39]	_	_
7-3	790-793	the	abstract[39]|abstract[40]	new[39]|giv[40]	coref	9-3[60_40]
7-4	794-804	microbiota	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
7-5	805-812	provide	_	_	_	_
7-6	813-822	plausible	abstract[41]	new[41]	coref	11-17[91_41]
7-7	823-832	candidate	abstract[41]	new[41]	_	_
7-8	833-843	mechanisms	abstract[41]	new[41]	_	_
7-9	844-847	for	abstract[41]	new[41]	_	_
7-10	848-855	driving	abstract[41]	new[41]	_	_
7-11	856-860	both	abstract[41]|abstract[42]	new[41]|new[42]	coref	18-18[0_42]
7-12	861-873	inflammation	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-13	874-877	and	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-14	878-886	altering	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-15	887-890	the	abstract[41]|abstract[42]|abstract[43]	new[41]|new[42]|new[43]	_	_
7-16	891-897	immune	abstract[41]|abstract[42]|abstract[43]	new[41]|new[42]|new[43]	_	_
7-17	898-906	response	abstract[41]|abstract[42]|abstract[43]	new[41]|new[42]|new[43]	_	_
7-18	907-910	and	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-19	911-915	host	abstract[41]|abstract[42]|animal|abstract[45]	new[41]|new[42]|new|new[45]	coref	9-11
7-20	916-926	metabolism	abstract[41]|abstract[42]|abstract[45]	new[41]|new[42]|new[45]	_	_
7-21	927-928	,	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-22	929-934	which	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-23	935-937	in	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-24	938-942	turn	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-25	943-946	may	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-26	947-955	modulate	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-27	956-959	the	abstract[41]|abstract[42]|event[46]	new[41]|new[42]|new[46]	_	_
7-28	960-971	development	abstract[41]|abstract[42]|event[46]	new[41]|new[42]|new[46]	_	_
7-29	972-974	of	abstract[41]|abstract[42]|event[46]	new[41]|new[42]|new[46]	_	_
7-30	975-990	musculoskeletal	abstract[41]|abstract[42]|event[46]|abstract[47]	new[41]|new[42]|new[46]|new[47]	_	_
7-31	991-999	problems	abstract[41]|abstract[42]|event[46]|abstract[47]	new[41]|new[42]|new[46]|new[47]	_	_
7-32	1000-1001	(	_	_	_	_
7-33	1002-1005	see	_	_	_	_
7-34	1006-1009	the	abstract[50]	new[50]	_	_
7-35	1010-1020	Prevotella	abstract|abstract[50]	new|new[50]	_	_
7-36	1021-1026	copri	person|abstract[50]	new|new[50]	coref	19-1[164_0]
7-37	1027-1031	case	abstract[50]	new[50]	_	_
7-38	1032-1037	below	_	_	_	_
7-39	1038-1039	)	_	_	_	_
7-40	1040-1041	.	_	_	_	_

#Text=The microbiome is thus a highly plausible target for the modulation of diseases of aging owing to its close relationship with innate and adaptive immune systems .
8-1	1042-1045	The	abstract[51]	giv[51]	coref	8-4[52_51]
8-2	1046-1056	microbiome	abstract[51]	giv[51]	_	_
8-3	1057-1059	is	_	_	_	_
8-4	1060-1064	thus	abstract[52]	giv[52]	ana	8-18[0_52]
8-5	1065-1066	a	abstract[52]	giv[52]	_	_
8-6	1067-1073	highly	abstract[52]	giv[52]	_	_
8-7	1074-1083	plausible	abstract[52]	giv[52]	_	_
8-8	1084-1090	target	abstract[52]	giv[52]	_	_
8-9	1091-1094	for	abstract[52]	giv[52]	_	_
8-10	1095-1098	the	abstract[52]|abstract[53]	giv[52]|new[53]	coref	14-5[0_53]
8-11	1099-1109	modulation	abstract[52]|abstract[53]	giv[52]|new[53]	_	_
8-12	1110-1112	of	abstract[52]|abstract[53]	giv[52]|new[53]	_	_
8-13	1113-1121	diseases	abstract[52]|abstract[53]|abstract[54]	giv[52]|new[53]|giv[54]	coref	9-25[68_54]
8-14	1122-1124	of	abstract[52]|abstract[53]|abstract[54]	giv[52]|new[53]|giv[54]	_	_
8-15	1125-1130	aging	abstract[52]|abstract[53]|abstract[54]|event	giv[52]|new[53]|giv[54]|new	_	_
8-16	1131-1136	owing	abstract[52]	giv[52]	_	_
8-17	1137-1139	to	abstract[52]	giv[52]	_	_
8-18	1140-1143	its	abstract[52]|abstract|abstract[57]	giv[52]|giv|new[57]	coref	20-24[175_0]
8-19	1144-1149	close	abstract[52]|abstract[57]	giv[52]|new[57]	_	_
8-20	1150-1162	relationship	abstract[52]|abstract[57]	giv[52]|new[57]	_	_
8-21	1163-1167	with	abstract[52]|abstract[57]	giv[52]|new[57]	_	_
8-22	1168-1174	innate	abstract[52]|abstract[57]|abstract[58]	giv[52]|new[57]|new[58]	_	_
8-23	1175-1178	and	abstract[52]|abstract[57]|abstract[58]	giv[52]|new[57]|new[58]	_	_
8-24	1179-1187	adaptive	abstract[52]|abstract[57]|abstract[58]	giv[52]|new[57]|new[58]	_	_
8-25	1188-1194	immune	abstract[52]|abstract[57]|abstract[58]	giv[52]|new[57]|new[58]	_	_
8-26	1195-1202	systems	abstract[52]|abstract[57]|abstract[58]	giv[52]|new[57]|new[58]	_	_
8-27	1203-1204	.	_	_	_	_

#Text=Components of intestinal microbiota can indeed direct key aspects of host immunity , in particular effector T-cell differentiation , which may impact susceptibility to autoimmune diseases and RA in particular .
9-1	1205-1215	Components	abstract[59]	new[59]	_	_
9-2	1216-1218	of	abstract[59]	new[59]	_	_
9-3	1219-1229	intestinal	abstract[59]|abstract[60]	new[59]|giv[60]	coref	11-8[88_60]
9-4	1230-1240	microbiota	abstract[59]|abstract[60]	new[59]|giv[60]	_	_
9-5	1241-1244	can	_	_	_	_
9-6	1245-1251	indeed	_	_	_	_
9-7	1252-1258	direct	_	_	_	_
9-8	1259-1262	key	abstract[61]	new[61]	_	_
9-9	1263-1270	aspects	abstract[61]	new[61]	_	_
9-10	1271-1273	of	abstract[61]	new[61]	_	_
9-11	1274-1278	host	abstract[61]|animal|abstract[63]	new[61]|giv|new[63]	coref	28-22
9-12	1279-1287	immunity	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-13	1288-1289	,	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-14	1290-1292	in	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-15	1293-1303	particular	abstract[61]|abstract[63]|abstract[66]	new[61]|new[63]|new[66]	coref	11-25[92_66]
9-16	1304-1312	effector	abstract[61]|abstract[63]|abstract|abstract[66]	new[61]|new[63]|new|new[66]	_	_
9-17	1313-1319	T-cell	abstract[61]|abstract[63]|abstract|abstract[66]	new[61]|new[63]|new|new[66]	_	_
9-18	1320-1335	differentiation	abstract[61]|abstract[63]|abstract[66]	new[61]|new[63]|new[66]	_	_
9-19	1336-1337	,	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-20	1338-1343	which	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-21	1344-1347	may	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-22	1348-1354	impact	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-23	1355-1369	susceptibility	abstract[61]|abstract[63]|abstract[67]	new[61]|new[63]|new[67]	_	_
9-24	1370-1372	to	abstract[61]|abstract[63]|abstract[67]	new[61]|new[63]|new[67]	_	_
9-25	1373-1383	autoimmune	abstract[61]|abstract[63]|abstract[67]|abstract[68]|abstract[69]	new[61]|new[63]|new[67]|giv[68]|giv[69]	coref|coref	9-25[69_68]|12-47[113_69]
9-26	1384-1392	diseases	abstract[61]|abstract[63]|abstract[67]|abstract[68]|abstract[69]	new[61]|new[63]|new[67]|giv[68]|giv[69]	_	_
9-27	1393-1396	and	abstract[61]|abstract[63]|abstract[67]|abstract[69]	new[61]|new[63]|new[67]|giv[69]	_	_
9-28	1397-1399	RA	abstract[61]|abstract[63]|abstract[67]|abstract[69]|organization	new[61]|new[63]|new[67]|giv[69]|giv	coref	10-7
9-29	1400-1402	in	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-30	1403-1413	particular	abstract[61]|abstract[63]	new[61]|new[63]	_	_
9-31	1414-1415	.	_	_	_	_

#Text=Different studies investigating the etiology of RA have established the involvement of regulatory T ( T-reg ) cells , which are defective at suppressing IFN-γ and TNF-α production by conventional T cells in the peripheral blood of active RA patients .
10-1	1416-1425	Different	abstract[71]	new[71]	coref	20-1[172_71]
10-2	1426-1433	studies	abstract[71]	new[71]	_	_
10-3	1434-1447	investigating	abstract[71]	new[71]	_	_
10-4	1448-1451	the	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-5	1452-1460	etiology	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-6	1461-1463	of	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-7	1464-1466	RA	abstract[71]|abstract[72]|organization	new[71]|new[72]|giv	coref	10-39
10-8	1467-1471	have	_	_	_	_
10-9	1472-1483	established	_	_	_	_
10-10	1484-1487	the	abstract[74]	new[74]	_	_
10-11	1488-1499	involvement	abstract[74]	new[74]	_	_
10-12	1500-1502	of	abstract[74]	new[74]	_	_
10-13	1503-1513	regulatory	abstract[74]|person[75]|animal[77]	new[74]|new[75]|new[77]	coref|coref	10-31[0_75]|10-30[82_77]
10-14	1514-1515	T	abstract[74]|person[75]|animal[77]	new[74]|new[75]|new[77]	_	_
10-15	1516-1517	(	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-16	1518-1523	T-reg	abstract[74]|animal|animal[77]	new[74]|new|new[77]	coref	11-34
10-17	1524-1525	)	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-18	1526-1531	cells	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-19	1532-1533	,	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-20	1534-1539	which	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-21	1540-1543	are	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-22	1544-1553	defective	abstract[74]|animal[77]	new[74]|new[77]	_	_
10-23	1554-1556	at	_	_	_	_
10-24	1557-1568	suppressing	_	_	_	_
10-25	1569-1574	IFN-γ	abstract|abstract[80]	new|new[80]	ana	11-1[0_80]
10-26	1575-1578	and	abstract[80]	new[80]	_	_
10-27	1579-1584	TNF-α	object|abstract[80]	new|new[80]	_	_
10-28	1585-1595	production	abstract[80]	new[80]	_	_
10-29	1596-1598	by	_	_	_	_
10-30	1599-1611	conventional	animal[82]	giv[82]	_	_
10-31	1612-1613	T	person|animal[82]	giv|giv[82]	coref	11-29
10-32	1614-1619	cells	animal[82]	giv[82]	_	_
10-33	1620-1622	in	_	_	_	_
10-34	1623-1626	the	substance[83]	new[83]	_	_
10-35	1627-1637	peripheral	substance[83]	new[83]	_	_
10-36	1638-1643	blood	substance[83]	new[83]	_	_
10-37	1644-1646	of	substance[83]	new[83]	_	_
10-38	1647-1653	active	substance[83]|person[85]	new[83]|giv[85]	coref	18-40[160_85]
10-39	1654-1656	RA	substance[83]|organization|person[85]	new[83]|giv|giv[85]	coref	17-20
10-40	1657-1665	patients	substance[83]|person[85]	new[83]|giv[85]	_	_
10-41	1666-1667	.	_	_	_	_

#Text=It has been well established that the gut microbiota – immune interaction and homeostasis , via balancing pro- and anti-inflammatory mechanisms , can regulate the differentiation of various T cell types , especially T-reg cells .
11-1	1668-1670	It	abstract	giv	_	_
11-2	1671-1674	has	_	_	_	_
11-3	1675-1679	been	_	_	_	_
11-4	1680-1684	well	_	_	_	_
11-5	1685-1696	established	_	_	_	_
11-6	1697-1701	that	_	_	_	_
11-7	1702-1705	the	abstract[89]	new[89]	_	_
11-8	1706-1709	gut	abstract|abstract[88]|abstract[89]	giv|giv[88]|new[89]	coref|coref	15-6[0_88]|16-9
11-9	1710-1720	microbiota	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
11-10	1721-1722	–	abstract[89]	new[89]	_	_
11-11	1723-1729	immune	abstract[89]	new[89]	_	_
11-12	1730-1741	interaction	abstract[89]	new[89]	_	_
11-13	1742-1745	and	_	_	_	_
11-14	1746-1757	homeostasis	abstract	new	_	_
11-15	1758-1759	,	_	_	_	_
11-16	1760-1763	via	_	_	_	_
11-17	1764-1773	balancing	abstract[91]	giv[91]	_	_
11-18	1774-1778	pro-	abstract[91]	giv[91]	_	_
11-19	1779-1782	and	abstract[91]	giv[91]	_	_
11-20	1783-1800	anti-inflammatory	abstract[91]	giv[91]	_	_
11-21	1801-1811	mechanisms	abstract[91]	giv[91]	_	_
11-22	1812-1813	,	_	_	_	_
11-23	1814-1817	can	_	_	_	_
11-24	1818-1826	regulate	_	_	_	_
11-25	1827-1830	the	abstract[92]	giv[92]	coref	12-35[109_92]
11-26	1831-1846	differentiation	abstract[92]	giv[92]	_	_
11-27	1847-1849	of	abstract[92]	giv[92]	_	_
11-28	1850-1857	various	abstract[92]|animal[95]	giv[92]|new[95]	appos	11-33[97_95]
11-29	1858-1859	T	abstract[92]|person|animal[94]|animal[95]	giv[92]|giv|new[94]|new[95]	coref|coref	12-36[0_94]|14-14
11-30	1860-1864	cell	abstract[92]|animal[94]|animal[95]	giv[92]|new[94]|new[95]	_	_
11-31	1865-1870	types	abstract[92]|animal[95]	giv[92]|new[95]	_	_
11-32	1871-1872	,	_	_	_	_
11-33	1873-1883	especially	animal[97]	giv[97]	coref	14-13[129_97]
11-34	1884-1889	T-reg	animal|animal[97]	giv|giv[97]	coref	12-35
11-35	1890-1895	cells	animal[97]	giv[97]	_	_
11-36	1896-1897	.	_	_	_	_

#Text=A clear example is the potential therapeutic effect of SCFAs ( short chain fatty acids ) , which are microbial fermentation products found in the bowel , that have demonstrated a profound influence on T-reg cell differentiation in a variety of experimental models of autoimmunity or inflammatory T-cell-mediated diseases .
12-1	1898-1899	A	abstract[98]	new[98]	coref	12-5[99_98]
12-2	1900-1905	clear	abstract[98]	new[98]	_	_
12-3	1906-1913	example	abstract[98]	new[98]	_	_
12-4	1914-1916	is	_	_	_	_
12-5	1917-1920	the	abstract[99]	giv[99]	_	_
12-6	1921-1930	potential	abstract[99]	giv[99]	_	_
12-7	1931-1942	therapeutic	abstract[99]	giv[99]	_	_
12-8	1943-1949	effect	abstract[99]	giv[99]	_	_
12-9	1950-1952	of	abstract[99]	giv[99]	_	_
12-10	1953-1958	SCFAs	abstract[99]|abstract	giv[99]|new	_	_
12-11	1959-1960	(	_	_	_	_
12-12	1961-1966	short	substance[102]	new[102]	_	_
12-13	1967-1972	chain	substance[102]	new[102]	_	_
12-14	1973-1978	fatty	abstract|substance[102]	new|new[102]	_	_
12-15	1979-1984	acids	substance[102]	new[102]	_	_
12-16	1985-1986	)	_	_	_	_
12-17	1987-1988	,	_	_	_	_
12-18	1989-1994	which	substance[104]	new[104]	_	_
12-19	1995-1998	are	substance[104]	new[104]	_	_
12-20	1999-2008	microbial	substance[104]	new[104]	_	_
12-21	2009-2021	fermentation	abstract|substance[104]	new|new[104]	_	_
12-22	2022-2030	products	substance[104]	new[104]	_	_
12-23	2031-2036	found	substance[104]	new[104]	_	_
12-24	2037-2039	in	substance[104]	new[104]	_	_
12-25	2040-2043	the	substance[104]|object[105]	new[104]|new[105]	_	_
12-26	2044-2049	bowel	substance[104]|object[105]	new[104]|new[105]	_	_
12-27	2050-2051	,	_	_	_	_
12-28	2052-2056	that	_	_	_	_
12-29	2057-2061	have	_	_	_	_
12-30	2062-2074	demonstrated	_	_	_	_
12-31	2075-2076	a	abstract[106]	new[106]	_	_
12-32	2077-2085	profound	abstract[106]	new[106]	_	_
12-33	2086-2095	influence	abstract[106]	new[106]	_	_
12-34	2096-2098	on	abstract[106]	new[106]	_	_
12-35	2099-2104	T-reg	abstract[106]|animal|abstract[109]	new[106]|giv|giv[109]	coref	14-17
12-36	2105-2109	cell	abstract[106]|animal|abstract[109]	new[106]|giv|giv[109]	_	_
12-37	2110-2125	differentiation	abstract[106]|abstract[109]	new[106]|giv[109]	_	_
12-38	2126-2128	in	_	_	_	_
12-39	2129-2130	a	abstract[110]	new[110]	_	_
12-40	2131-2138	variety	abstract[110]	new[110]	_	_
12-41	2139-2141	of	abstract[110]	new[110]	_	_
12-42	2142-2154	experimental	abstract[110]|abstract[111]	new[110]|new[111]	_	_
12-43	2155-2161	models	abstract[110]|abstract[111]	new[110]|new[111]	_	_
12-44	2162-2164	of	abstract[110]|abstract[111]	new[110]|new[111]	_	_
12-45	2165-2177	autoimmunity	abstract[110]|abstract[111]|abstract	new[110]|new[111]|new	_	_
12-46	2178-2180	or	abstract[110]|abstract[111]	new[110]|new[111]	_	_
12-47	2181-2193	inflammatory	abstract[110]|abstract[111]|abstract[113]	new[110]|new[111]|giv[113]	_	_
12-48	2194-2209	T-cell-mediated	abstract[110]|abstract[111]|abstract[113]	new[110]|new[111]|giv[113]	_	_
12-49	2210-2218	diseases	abstract[110]|abstract[111]|abstract[113]	new[110]|new[111]|giv[113]	_	_
12-50	2219-2220	.	_	_	_	_

#Text=An elegant collagen-induced arthritis mouse model published by Hui et al. demonstrated that butyrate ( a functional SCFA ) administration inhibited arthritis by suppressing the expression of inflammatory cytokines .
13-1	2221-2223	An	abstract[116]	new[116]	_	_
13-2	2224-2231	elegant	abstract[116]	new[116]	_	_
13-3	2232-2248	collagen-induced	person[114]|abstract[116]	new[114]|new[116]	_	_
13-4	2249-2258	arthritis	person[114]|abstract[116]	new[114]|new[116]	_	_
13-5	2259-2264	mouse	animal|abstract[116]	new|new[116]	_	_
13-6	2265-2270	model	abstract[116]	new[116]	_	_
13-7	2271-2280	published	abstract[116]	new[116]	_	_
13-8	2281-2283	by	abstract[116]	new[116]	_	_
13-9	2284-2287	Hui	abstract[116]|person	new[116]|new	_	_
13-10	2288-2290	et	abstract[116]	new[116]	_	_
13-11	2291-2294	al.	abstract[116]	new[116]	_	_
13-12	2295-2307	demonstrated	_	_	_	_
13-13	2308-2312	that	_	_	_	_
13-14	2313-2321	butyrate	substance	new	appos	13-16[119_0]
13-15	2322-2323	(	_	_	_	_
13-16	2324-2325	a	substance[119]	giv[119]	_	_
13-17	2326-2336	functional	substance[119]	giv[119]	_	_
13-18	2337-2341	SCFA	substance[119]	giv[119]	_	_
13-19	2342-2343	)	_	_	_	_
13-20	2344-2358	administration	organization	new	_	_
13-21	2359-2368	inhibited	_	_	_	_
13-22	2369-2378	arthritis	abstract	new	coref	15-13[138_0]
13-23	2379-2381	by	_	_	_	_
13-24	2382-2393	suppressing	_	_	_	_
13-25	2394-2397	the	abstract[122]	new[122]	_	_
13-26	2398-2408	expression	abstract[122]	new[122]	_	_
13-27	2409-2411	of	abstract[122]	new[122]	_	_
13-28	2412-2424	inflammatory	abstract[122]|abstract[123]	new[122]|new[123]	_	_
13-29	2425-2434	cytokines	abstract[122]|abstract[123]	new[122]|new[123]	_	_
13-30	2435-2436	.	_	_	_	_

#Text=The authors suggested that modulation was likely mediated by the differentiation of CD4 T cells towards T-reg cells , which produce anti-inflammatory cytokine IL-10 , and thus influenced the function of Th17 cells .
14-1	2437-2440	The	person[124]	new[124]	_	_
14-2	2441-2448	authors	person[124]	new[124]	_	_
14-3	2449-2458	suggested	_	_	_	_
14-4	2459-2463	that	_	_	_	_
14-5	2464-2474	modulation	abstract	giv	_	_
14-6	2475-2478	was	_	_	_	_
14-7	2479-2485	likely	_	_	_	_
14-8	2486-2494	mediated	_	_	_	_
14-9	2495-2497	by	_	_	_	_
14-10	2498-2501	the	event[126]	new[126]	_	_
14-11	2502-2517	differentiation	event[126]	new[126]	_	_
14-12	2518-2520	of	event[126]	new[126]	_	_
14-13	2521-2524	CD4	event[126]|abstract|animal[129]	new[126]|new|giv[129]	coref	14-17[131_129]
14-14	2525-2526	T	event[126]|person|animal[129]	new[126]|giv|giv[129]	_	_
14-15	2527-2532	cells	event[126]|animal[129]	new[126]|giv[129]	_	_
14-16	2533-2540	towards	event[126]	new[126]	_	_
14-17	2541-2546	T-reg	event[126]|animal|animal[131]	new[126]|giv|giv[131]	coref	14-32[135_131]
14-18	2547-2552	cells	event[126]|animal[131]	new[126]|giv[131]	_	_
14-19	2553-2554	,	event[126]|animal[131]	new[126]|giv[131]	_	_
14-20	2555-2560	which	event[126]|animal[131]	new[126]|giv[131]	_	_
14-21	2561-2568	produce	event[126]|animal[131]	new[126]|giv[131]	_	_
14-22	2569-2586	anti-inflammatory	event[126]|animal[131]|abstract[132]	new[126]|giv[131]|new[132]	_	_
14-23	2587-2595	cytokine	event[126]|animal[131]|abstract[132]	new[126]|giv[131]|new[132]	_	_
14-24	2596-2601	IL-10	event[126]|animal[131]	new[126]|giv[131]	_	_
14-25	2602-2603	,	event[126]|animal[131]	new[126]|giv[131]	_	_
14-26	2604-2607	and	event[126]|animal[131]	new[126]|giv[131]	_	_
14-27	2608-2612	thus	event[126]|animal[131]	new[126]|giv[131]	_	_
14-28	2613-2623	influenced	event[126]|animal[131]	new[126]|giv[131]	_	_
14-29	2624-2627	the	event[126]|animal[131]|abstract[133]	new[126]|giv[131]|new[133]	_	_
14-30	2628-2636	function	event[126]|animal[131]|abstract[133]	new[126]|giv[131]|new[133]	_	_
14-31	2637-2639	of	event[126]|animal[131]|abstract[133]	new[126]|giv[131]|new[133]	_	_
14-32	2640-2644	Th17	event[126]|animal[131]|abstract[133]|substance|animal[135]	new[126]|giv[131]|new[133]|new|giv[135]	_	_
14-33	2645-2650	cells	event[126]|animal[131]|abstract[133]|animal[135]	new[126]|giv[131]|new[133]|giv[135]	_	_
14-34	2651-2652	.	_	_	_	_

#Text=As mentioned , an altered microbiota profile has also been associated with juvenile idiopathic arthritis ( JIA ) .
15-1	2653-2655	As	_	_	_	_
15-2	2656-2665	mentioned	_	_	_	_
15-3	2666-2667	,	_	_	_	_
15-4	2668-2670	an	abstract[137]	new[137]	_	_
15-5	2671-2678	altered	abstract[137]	new[137]	_	_
15-6	2679-2689	microbiota	abstract|abstract[137]	giv|new[137]	coref	16-9[143_0]
15-7	2690-2697	profile	abstract[137]	new[137]	_	_
15-8	2698-2701	has	_	_	_	_
15-9	2702-2706	also	_	_	_	_
15-10	2707-2711	been	_	_	_	_
15-11	2712-2722	associated	_	_	_	_
15-12	2723-2727	with	_	_	_	_
15-13	2728-2736	juvenile	abstract[138]	giv[138]	appos	15-17[0_138]
15-14	2737-2747	idiopathic	abstract[138]	giv[138]	_	_
15-15	2748-2757	arthritis	abstract[138]	giv[138]	_	_
15-16	2758-2759	(	_	_	_	_
15-17	2760-2763	JIA	abstract	giv	coref	16-17
15-18	2764-2765	)	_	_	_	_
15-19	2766-2767	.	_	_	_	_

#Text=Current evidence indeed suggests that the perturbation of gut microbiota may contribute to the development of JIA .
16-1	2768-2775	Current	abstract[140]	new[140]	_	_
16-2	2776-2784	evidence	abstract[140]	new[140]	_	_
16-3	2785-2791	indeed	_	_	_	_
16-4	2792-2800	suggests	_	_	_	_
16-5	2801-2805	that	_	_	_	_
16-6	2806-2809	the	abstract[141]	new[141]	_	_
16-7	2810-2822	perturbation	abstract[141]	new[141]	_	_
16-8	2823-2825	of	abstract[141]	new[141]	_	_
16-9	2826-2829	gut	abstract[141]|abstract|abstract[143]	new[141]|giv|giv[143]	coref|coref	21-4[179_143]|26-25
16-10	2830-2840	microbiota	abstract[141]|abstract[143]	new[141]|giv[143]	_	_
16-11	2841-2844	may	_	_	_	_
16-12	2845-2855	contribute	_	_	_	_
16-13	2856-2858	to	_	_	_	_
16-14	2859-2862	the	event[144]	new[144]	ana	17-1[0_144]
16-15	2863-2874	development	event[144]	new[144]	_	_
16-16	2875-2877	of	event[144]	new[144]	_	_
16-17	2878-2881	JIA	event[144]|abstract	new[144]|giv	_	_
16-18	2882-2883	.	_	_	_	_

#Text=It remains difficult , however , to establish a definitive microbial marker or specific enterotypes that are associated with RA .
17-1	2884-2886	It	event	giv	_	_
17-2	2887-2894	remains	_	_	_	_
17-3	2895-2904	difficult	_	_	_	_
17-4	2905-2906	,	_	_	_	_
17-5	2907-2914	however	_	_	_	_
17-6	2915-2916	,	_	_	_	_
17-7	2917-2919	to	_	_	_	_
17-8	2920-2929	establish	_	_	_	_
17-9	2930-2931	a	abstract[147]	new[147]	ana	18-1[0_147]
17-10	2932-2942	definitive	abstract[147]	new[147]	_	_
17-11	2943-2952	microbial	abstract[147]	new[147]	_	_
17-12	2953-2959	marker	abstract[147]	new[147]	_	_
17-13	2960-2962	or	_	_	_	_
17-14	2963-2971	specific	substance[148]	new[148]	_	_
17-15	2972-2983	enterotypes	substance[148]	new[148]	_	_
17-16	2984-2988	that	substance[148]	new[148]	_	_
17-17	2989-2992	are	substance[148]	new[148]	_	_
17-18	2993-3003	associated	substance[148]	new[148]	_	_
17-19	3004-3008	with	substance[148]	new[148]	_	_
17-20	3009-3011	RA	substance[148]|organization	new[148]|giv	coref	18-40
17-21	3012-3013	.	_	_	_	_

#Text=It has been hypothesized that the alteration of single bacterial genus could have direct impact on driving inflammation , as suggested for Bacteroides , Akkermansia or the anti-inflammatory Faecalobacterium prausnitzii , which has been noted to be depleted in RA patients , while Prevotella and Ruminococcus were more prevalent .
18-1	3014-3016	It	abstract	giv	_	_
18-2	3017-3020	has	_	_	_	_
18-3	3021-3025	been	_	_	_	_
18-4	3026-3038	hypothesized	_	_	_	_
18-5	3039-3043	that	_	_	_	_
18-6	3044-3047	the	event[151]	new[151]	_	_
18-7	3048-3058	alteration	event[151]	new[151]	_	_
18-8	3059-3061	of	event[151]	new[151]	_	_
18-9	3062-3068	single	event[151]|abstract[152]	new[151]|new[152]	_	_
18-10	3069-3078	bacterial	event[151]|abstract[152]	new[151]|new[152]	_	_
18-11	3079-3084	genus	event[151]|abstract[152]	new[151]|new[152]	_	_
18-12	3085-3090	could	_	_	_	_
18-13	3091-3095	have	_	_	_	_
18-14	3096-3102	direct	abstract[153]	new[153]	_	_
18-15	3103-3109	impact	abstract[153]	new[153]	_	_
18-16	3110-3112	on	_	_	_	_
18-17	3113-3120	driving	_	_	_	_
18-18	3121-3133	inflammation	abstract	giv	coref	31-6[251_0]
18-19	3134-3135	,	_	_	_	_
18-20	3136-3138	as	_	_	_	_
18-21	3139-3148	suggested	_	_	_	_
18-22	3149-3152	for	_	_	_	_
18-23	3153-3164	Bacteroides	animal	new	coref	19-6
18-24	3165-3166	,	_	_	_	_
18-25	3167-3178	Akkermansia	person	new	_	_
18-26	3179-3181	or	_	_	_	_
18-27	3182-3185	the	animal[158]	new[158]	_	_
18-28	3186-3203	anti-inflammatory	animal[158]	new[158]	_	_
18-29	3204-3220	Faecalobacterium	animal|animal[158]	new|new[158]	_	_
18-30	3221-3232	prausnitzii	animal[158]	new[158]	_	_
18-31	3233-3234	,	animal[158]	new[158]	_	_
18-32	3235-3240	which	animal[158]	new[158]	_	_
18-33	3241-3244	has	animal[158]	new[158]	_	_
18-34	3245-3249	been	animal[158]	new[158]	_	_
18-35	3250-3255	noted	animal[158]	new[158]	_	_
18-36	3256-3258	to	animal[158]	new[158]	_	_
18-37	3259-3261	be	animal[158]	new[158]	_	_
18-38	3262-3270	depleted	animal[158]	new[158]	_	_
18-39	3271-3273	in	_	_	_	_
18-40	3274-3276	RA	organization|person[160]	giv|giv[160]	coref|coref	19-19[170_0]|32-36[273_160]
18-41	3277-3285	patients	person[160]	giv[160]	_	_
18-42	3286-3287	,	_	_	_	_
18-43	3288-3293	while	_	_	_	_
18-44	3294-3304	Prevotella	person	new	coref	19-2
18-45	3305-3308	and	_	_	_	_
18-46	3309-3321	Ruminococcus	substance	new	_	_
18-47	3322-3326	were	_	_	_	_
18-48	3327-3331	more	_	_	_	_
18-49	3332-3341	prevalent	_	_	_	_
18-50	3342-3343	.	_	_	_	_

#Text=Increasing Prevotella copri and decreasing Bacteroides concentrations in the stool have both been associated with new onset , untreated RA in humans .
19-1	3344-3354	Increasing	person[164]	giv[164]	_	_
19-2	3355-3365	Prevotella	person|person[164]	giv|giv[164]	_	_
19-3	3366-3371	copri	person[164]	giv[164]	_	_
19-4	3372-3375	and	_	_	_	_
19-5	3376-3386	decreasing	animal[166]	new[166]	coref	32-8[266_166]
19-6	3387-3398	Bacteroides	animal|animal[166]	giv|new[166]	coref	26-32
19-7	3399-3413	concentrations	animal[166]	new[166]	_	_
19-8	3414-3416	in	animal[166]	new[166]	_	_
19-9	3417-3420	the	animal[166]|object[167]	new[166]|new[167]	_	_
19-10	3421-3426	stool	animal[166]|object[167]	new[166]|new[167]	_	_
19-11	3427-3431	have	_	_	_	_
19-12	3432-3436	both	_	_	_	_
19-13	3437-3441	been	_	_	_	_
19-14	3442-3452	associated	_	_	_	_
19-15	3453-3457	with	_	_	_	_
19-16	3458-3461	new	abstract[168]|abstract[169]	new[168]|new[169]	coref|coref	32-29[269_168]|32-29[270_169]
19-17	3462-3467	onset	abstract[168]|abstract[169]	new[168]|new[169]	_	_
19-18	3468-3469	,	abstract[169]	new[169]	_	_
19-19	3470-3479	untreated	abstract[169]|organization[170]	new[169]|giv[170]	_	_
19-20	3480-3482	RA	abstract[169]|organization[170]	new[169]|giv[170]	_	_
19-21	3483-3485	in	_	_	_	_
19-22	3486-3492	humans	animal	new	_	_
19-23	3493-3494	.	_	_	_	_

#Text=The above studies , although not always homogenous , have directly or indirectly demonstrated that genetic risk may be modulated by alterations in the microbiome and that the presence of particular microbial markers can be predictive of disease .
20-1	3495-3498	The	abstract[172]	giv[172]	_	_
20-2	3499-3504	above	abstract[172]	giv[172]	_	_
20-3	3505-3512	studies	abstract[172]	giv[172]	_	_
20-4	3513-3514	,	_	_	_	_
20-5	3515-3523	although	_	_	_	_
20-6	3524-3527	not	_	_	_	_
20-7	3528-3534	always	_	_	_	_
20-8	3535-3545	homogenous	_	_	_	_
20-9	3546-3547	,	_	_	_	_
20-10	3548-3552	have	_	_	_	_
20-11	3553-3561	directly	_	_	_	_
20-12	3562-3564	or	_	_	_	_
20-13	3565-3575	indirectly	_	_	_	_
20-14	3576-3588	demonstrated	_	_	_	_
20-15	3589-3593	that	_	_	_	_
20-16	3594-3601	genetic	abstract[173]	new[173]	coref	24-14[0_173]
20-17	3602-3606	risk	abstract[173]	new[173]	_	_
20-18	3607-3610	may	_	_	_	_
20-19	3611-3613	be	_	_	_	_
20-20	3614-3623	modulated	_	_	_	_
20-21	3624-3626	by	_	_	_	_
20-22	3627-3638	alterations	abstract[174]	giv[174]	_	_
20-23	3639-3641	in	abstract[174]	giv[174]	_	_
20-24	3642-3645	the	abstract[174]|abstract[175]	giv[174]|giv[175]	coref	29-18[241_175]
20-25	3646-3656	microbiome	abstract[174]|abstract[175]	giv[174]|giv[175]	_	_
20-26	3657-3660	and	_	_	_	_
20-27	3661-3665	that	_	_	_	_
20-28	3666-3669	the	abstract[176]	new[176]	_	_
20-29	3670-3678	presence	abstract[176]	new[176]	_	_
20-30	3679-3681	of	abstract[176]	new[176]	_	_
20-31	3682-3692	particular	abstract[176]|abstract[177]	new[176]|new[177]	_	_
20-32	3693-3702	microbial	abstract[176]|abstract[177]	new[176]|new[177]	_	_
20-33	3703-3710	markers	abstract[176]|abstract[177]	new[176]|new[177]	_	_
20-34	3711-3714	can	_	_	_	_
20-35	3715-3717	be	_	_	_	_
20-36	3718-3728	predictive	_	_	_	_
20-37	3729-3731	of	_	_	_	_
20-38	3732-3739	disease	abstract	new	coref	22-20
20-39	3740-3741	.	_	_	_	_

#Text=As mentioned , intestinal microbiota are also known to change with age .
21-1	3742-3744	As	_	_	_	_
21-2	3745-3754	mentioned	_	_	_	_
21-3	3755-3756	,	_	_	_	_
21-4	3757-3767	intestinal	abstract[179]	giv[179]	coref	25-11[204_179]
21-5	3768-3778	microbiota	abstract[179]	giv[179]	_	_
21-6	3779-3782	are	_	_	_	_
21-7	3783-3787	also	_	_	_	_
21-8	3788-3793	known	_	_	_	_
21-9	3794-3796	to	_	_	_	_
21-10	3797-3803	change	event	new	coref|none	22-13[183_0]|21-10[0_183]
21-11	3804-3808	with	_	_	_	_
21-12	3809-3812	age	abstract	new	coref	22-24
21-13	3813-3814	.	_	_	_	_

#Text=Many of the clinical issues , including OA , are related to the inflammatory change — either specific to disease or associated with age .
22-1	3815-3819	Many	_	_	_	_
22-2	3820-3822	of	_	_	_	_
22-3	3823-3826	the	abstract[181]	new[181]	_	_
22-4	3827-3835	clinical	abstract[181]	new[181]	_	_
22-5	3836-3842	issues	abstract[181]	new[181]	_	_
22-6	3843-3844	,	abstract[181]	new[181]	_	_
22-7	3845-3854	including	abstract[181]	new[181]	_	_
22-8	3855-3857	OA	abstract[181]|abstract	new[181]|new	coref	23-1
22-9	3858-3859	,	_	_	_	_
22-10	3860-3863	are	_	_	_	_
22-11	3864-3871	related	_	_	_	_
22-12	3872-3874	to	_	_	_	_
22-13	3875-3878	the	event[183]	new[183]	_	_
22-14	3879-3891	inflammatory	event[183]	new[183]	_	_
22-15	3892-3898	change	event[183]	new[183]	_	_
22-16	3899-3900	—	_	_	_	_
22-17	3901-3907	either	_	_	_	_
22-18	3908-3916	specific	_	_	_	_
22-19	3917-3919	to	_	_	_	_
22-20	3920-3927	disease	abstract	giv	coref	24-22[196_0]
22-21	3928-3930	or	_	_	_	_
22-22	3931-3941	associated	_	_	_	_
22-23	3942-3946	with	_	_	_	_
22-24	3947-3950	age	abstract	giv	coref	23-18[190_0]
22-25	3951-3952	.	_	_	_	_

#Text=OA is indeed considered a degeneration of joint cartilage and the underlying bone which commonly occurs from middle age onward .
23-1	3953-3955	OA	abstract	giv	coref	24-5
23-2	3956-3958	is	_	_	_	_
23-3	3959-3965	indeed	_	_	_	_
23-4	3966-3976	considered	_	_	_	_
23-5	3977-3978	a	abstract[187]	new[187]	_	_
23-6	3979-3991	degeneration	abstract[187]	new[187]	_	_
23-7	3992-3994	of	abstract[187]	new[187]	_	_
23-8	3995-4000	joint	abstract[187]|object[188]	new[187]|new[188]	_	_
23-9	4001-4010	cartilage	abstract[187]|object[188]	new[187]|new[188]	_	_
23-10	4011-4014	and	abstract[187]	new[187]	_	_
23-11	4015-4018	the	abstract[187]|object[189]	new[187]|new[189]	_	_
23-12	4019-4029	underlying	abstract[187]|object[189]	new[187]|new[189]	_	_
23-13	4030-4034	bone	abstract[187]|object[189]	new[187]|new[189]	_	_
23-14	4035-4040	which	abstract[187]	new[187]	_	_
23-15	4041-4049	commonly	abstract[187]	new[187]	_	_
23-16	4050-4056	occurs	abstract[187]	new[187]	_	_
23-17	4057-4061	from	abstract[187]	new[187]	_	_
23-18	4062-4068	middle	abstract[187]|abstract[190]	new[187]|giv[190]	coref	24-26[0_190]
23-19	4069-4072	age	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
23-20	4073-4079	onward	abstract[187]	new[187]	_	_
23-21	4080-4081	.	_	_	_	_

#Text=The precise etiology of OA remains unknown thus far , even if various risk factors have been associated with presence of the disease , including age , sex , obesity , and diet , and local joint injury .
24-1	4082-4085	The	abstract[191]	new[191]	_	_
24-2	4086-4093	precise	abstract[191]	new[191]	_	_
24-3	4094-4102	etiology	abstract[191]	new[191]	_	_
24-4	4103-4105	of	abstract[191]	new[191]	_	_
24-5	4106-4108	OA	abstract[191]|abstract	new[191]|giv	coref	29-5
24-6	4109-4116	remains	_	_	_	_
24-7	4117-4124	unknown	_	_	_	_
24-8	4125-4129	thus	_	_	_	_
24-9	4130-4133	far	_	_	_	_
24-10	4134-4135	,	_	_	_	_
24-11	4136-4140	even	_	_	_	_
24-12	4141-4143	if	_	_	_	_
24-13	4144-4151	various	abstract[194]	new[194]	coref	25-1[202_194]
24-14	4152-4156	risk	abstract|abstract[194]	giv|new[194]	_	_
24-15	4157-4164	factors	abstract[194]	new[194]	_	_
24-16	4165-4169	have	_	_	_	_
24-17	4170-4174	been	_	_	_	_
24-18	4175-4185	associated	_	_	_	_
24-19	4186-4190	with	_	_	_	_
24-20	4191-4199	presence	abstract[195]	new[195]	_	_
24-21	4200-4202	of	abstract[195]	new[195]	_	_
24-22	4203-4206	the	abstract[195]|abstract[196]	new[195]|giv[196]	_	_
24-23	4207-4214	disease	abstract[195]|abstract[196]	new[195]|giv[196]	_	_
24-24	4215-4216	,	abstract[195]	new[195]	_	_
24-25	4217-4226	including	abstract[195]	new[195]	_	_
24-26	4227-4230	age	abstract[195]|abstract	new[195]|giv	_	_
24-27	4231-4232	,	abstract[195]	new[195]	_	_
24-28	4233-4236	sex	abstract[195]|abstract	new[195]|new	_	_
24-29	4237-4238	,	abstract[195]	new[195]	_	_
24-30	4239-4246	obesity	abstract[195]|abstract	new[195]|new	coref	27-4
24-31	4247-4248	,	abstract[195]	new[195]	_	_
24-32	4249-4252	and	abstract[195]	new[195]	_	_
24-33	4253-4257	diet	abstract[195]|event	new[195]|new	coref	28-3
24-34	4258-4259	,	abstract[195]	new[195]	_	_
24-35	4260-4263	and	abstract[195]	new[195]	_	_
24-36	4264-4269	local	abstract[195]|event[201]	new[195]|new[201]	_	_
24-37	4270-4275	joint	abstract[195]|event[201]	new[195]|new[201]	_	_
24-38	4276-4282	injury	abstract[195]|event[201]	new[195]|new[201]	_	_
24-39	4283-4284	.	_	_	_	_

#Text=Most of these factors are associated with drastic changes in the intestinal microbiota .
25-1	4285-4289	Most	abstract[202]	giv[202]	coref	29-25[243_202]
25-2	4290-4292	of	abstract[202]	giv[202]	_	_
25-3	4293-4298	these	abstract[202]	giv[202]	_	_
25-4	4299-4306	factors	abstract[202]	giv[202]	_	_
25-5	4307-4310	are	_	_	_	_
25-6	4311-4321	associated	_	_	_	_
25-7	4322-4326	with	_	_	_	_
25-8	4327-4334	drastic	event[203]	new[203]	coref	27-8[221_203]
25-9	4335-4342	changes	event[203]	new[203]	_	_
25-10	4343-4345	in	event[203]	new[203]	_	_
25-11	4346-4349	the	event[203]|abstract[204]	new[203]|giv[204]	coref	26-7[206_204]
25-12	4350-4360	intestinal	event[203]|abstract[204]	new[203]|giv[204]	_	_
25-13	4361-4371	microbiota	event[203]|abstract[204]	new[203]|giv[204]	_	_
25-14	4372-4373	.	_	_	_	_

#Text=Age , in fact , shifts the intestinal microbiota with significant differences between younger adults and older people , showing a lower diversity of gut microbiota , a greater proportion of Bacteroides spp. , and a distinct abundance pattern of Clostridium groups .
26-1	4374-4377	Age	abstract	new	_	_
26-2	4378-4379	,	_	_	_	_
26-3	4380-4382	in	_	_	_	_
26-4	4383-4387	fact	_	_	_	_
26-5	4388-4389	,	_	_	_	_
26-6	4390-4396	shifts	_	_	_	_
26-7	4397-4400	the	abstract[206]	giv[206]	coref	26-25[212_206]
26-8	4401-4411	intestinal	abstract[206]	giv[206]	_	_
26-9	4412-4422	microbiota	abstract[206]	giv[206]	_	_
26-10	4423-4427	with	_	_	_	_
26-11	4428-4439	significant	abstract[207]	new[207]	_	_
26-12	4440-4451	differences	abstract[207]	new[207]	_	_
26-13	4452-4459	between	abstract[207]	new[207]	_	_
26-14	4460-4467	younger	abstract[207]|person[208]	new[207]|new[208]	_	_
26-15	4468-4474	adults	abstract[207]|person[208]	new[207]|new[208]	_	_
26-16	4475-4478	and	abstract[207]	new[207]	_	_
26-17	4479-4484	older	abstract[207]|person[209]	new[207]|new[209]	_	_
26-18	4485-4491	people	abstract[207]|person[209]	new[207]|new[209]	_	_
26-19	4492-4493	,	_	_	_	_
26-20	4494-4501	showing	_	_	_	_
26-21	4502-4503	a	abstract[210]	new[210]	coref	27-21[225_210]
26-22	4504-4509	lower	abstract[210]	new[210]	_	_
26-23	4510-4519	diversity	abstract[210]	new[210]	_	_
26-24	4520-4522	of	abstract[210]	new[210]	_	_
26-25	4523-4526	gut	abstract[210]|abstract|abstract[212]	new[210]|giv|giv[212]	coref|coref	27-11[222_212]|28-6
26-26	4527-4537	microbiota	abstract[210]|abstract[212]	new[210]|giv[212]	_	_
26-27	4538-4539	,	_	_	_	_
26-28	4540-4541	a	animal[213]	new[213]	_	_
26-29	4542-4549	greater	animal[213]	new[213]	_	_
26-30	4550-4560	proportion	animal[213]	new[213]	_	_
26-31	4561-4563	of	animal[213]	new[213]	_	_
26-32	4564-4575	Bacteroides	animal[213]|animal|animal[215]	new[213]|giv|new[215]	_	_
26-33	4576-4580	spp.	animal[213]|animal[215]	new[213]|new[215]	_	_
26-34	4581-4582	,	_	_	_	_
26-35	4583-4586	and	_	_	_	_
26-36	4587-4588	a	abstract[217]	new[217]	_	_
26-37	4589-4597	distinct	abstract[217]	new[217]	_	_
26-38	4598-4607	abundance	abstract|abstract[217]	new|new[217]	_	_
26-39	4608-4615	pattern	abstract[217]	new[217]	_	_
26-40	4616-4618	of	abstract[217]	new[217]	_	_
26-41	4619-4630	Clostridium	abstract[217]|organization|animal[219]	new[217]|new|new[219]	_	_
26-42	4631-4637	groups	abstract[217]|animal[219]	new[217]|new[219]	_	_
26-43	4638-4639	.	_	_	_	_

#Text=In addition , obesity is associated with phylum-level changes in the microbiota ( i.e. , ratio of Firmicutes/Bacteroidetes ) , reduced bacterial diversity , and an altered representation of bacterial genes and metabolic pathways .
27-1	4640-4642	In	_	_	_	_
27-2	4643-4651	addition	_	_	_	_
27-3	4652-4653	,	_	_	_	_
27-4	4654-4661	obesity	abstract	giv	_	_
27-5	4662-4664	is	_	_	_	_
27-6	4665-4675	associated	_	_	_	_
27-7	4676-4680	with	_	_	_	_
27-8	4681-4693	phylum-level	event[221]	giv[221]	_	_
27-9	4694-4701	changes	event[221]	giv[221]	_	_
27-10	4702-4704	in	event[221]	giv[221]	_	_
27-11	4705-4708	the	event[221]|abstract[222]	giv[221]|giv[222]	coref	28-6[231_222]
27-12	4709-4719	microbiota	event[221]|abstract[222]	giv[221]|giv[222]	_	_
27-13	4720-4721	(	_	_	_	_
27-14	4722-4726	i.e.	abstract[223]	new[223]	_	_
27-15	4727-4728	,	abstract[223]	new[223]	_	_
27-16	4729-4734	ratio	abstract[223]	new[223]	_	_
27-17	4735-4737	of	abstract[223]	new[223]	_	_
27-18	4738-4762	Firmicutes/Bacteroidetes	abstract[223]|animal	new[223]|new	_	_
27-19	4763-4764	)	_	_	_	_
27-20	4765-4766	,	_	_	_	_
27-21	4767-4774	reduced	abstract[225]	giv[225]	_	_
27-22	4775-4784	bacterial	abstract[225]	giv[225]	_	_
27-23	4785-4794	diversity	abstract[225]	giv[225]	_	_
27-24	4795-4796	,	_	_	_	_
27-25	4797-4800	and	_	_	_	_
27-26	4801-4803	an	abstract[226]	new[226]	_	_
27-27	4804-4811	altered	abstract[226]	new[226]	_	_
27-28	4812-4826	representation	abstract[226]	new[226]	_	_
27-29	4827-4829	of	abstract[226]	new[226]	_	_
27-30	4830-4839	bacterial	abstract[226]|abstract[227]	new[226]|new[227]	_	_
27-31	4840-4845	genes	abstract[226]|abstract[227]	new[226]|new[227]	_	_
27-32	4846-4849	and	abstract[226]	new[226]	_	_
27-33	4850-4859	metabolic	abstract[226]|abstract[228]	new[226]|new[228]	_	_
27-34	4860-4868	pathways	abstract[226]|abstract[228]	new[226]|new[228]	_	_
27-35	4869-4870	.	_	_	_	_

#Text=Finally , diet can shape gut microbiota and consequently change the composition and metabolism of intestinal microbiota as well as impact host immune responses .
28-1	4871-4878	Finally	_	_	_	_
28-2	4879-4880	,	_	_	_	_
28-3	4881-4885	diet	event	giv	coref	31-13[252_0]
28-4	4886-4889	can	_	_	_	_
28-5	4890-4895	shape	_	_	_	_
28-6	4896-4899	gut	abstract|abstract[231]	giv|giv[231]	coref|coref	28-16[234_231]|30-14
28-7	4900-4910	microbiota	abstract[231]	giv[231]	_	_
28-8	4911-4914	and	_	_	_	_
28-9	4915-4927	consequently	_	_	_	_
28-10	4928-4934	change	_	_	_	_
28-11	4935-4938	the	abstract[232]	new[232]	_	_
28-12	4939-4950	composition	abstract[232]	new[232]	_	_
28-13	4951-4954	and	_	_	_	_
28-14	4955-4965	metabolism	substance[233]	new[233]	_	_
28-15	4966-4968	of	substance[233]	new[233]	_	_
28-16	4969-4979	intestinal	substance[233]|abstract[234]	new[233]|giv[234]	coref	30-14[249_234]
28-17	4980-4990	microbiota	substance[233]|abstract[234]	new[233]|giv[234]	_	_
28-18	4991-4993	as	_	_	_	_
28-19	4994-4998	well	_	_	_	_
28-20	4999-5001	as	_	_	_	_
28-21	5002-5008	impact	_	_	_	_
28-22	5009-5013	host	animal|abstract[236]	giv|new[236]	_	_
28-23	5014-5020	immune	abstract[236]	new[236]	_	_
28-24	5021-5030	responses	abstract[236]	new[236]	_	_
28-25	5031-5032	.	_	_	_	_

#Text=For these reasons , OA is now considered an induced inflammatory condition in which the role of the microbiome has emerging as one of the most important factors .
29-1	5033-5036	For	_	_	_	_
29-2	5037-5042	these	abstract[237]	new[237]	_	_
29-3	5043-5050	reasons	abstract[237]	new[237]	_	_
29-4	5051-5052	,	_	_	_	_
29-5	5053-5055	OA	abstract	giv	coref	32-34
29-6	5056-5058	is	_	_	_	_
29-7	5059-5062	now	_	_	_	_
29-8	5063-5073	considered	_	_	_	_
29-9	5074-5076	an	abstract[239]	new[239]	_	_
29-10	5077-5084	induced	abstract[239]	new[239]	_	_
29-11	5085-5097	inflammatory	abstract[239]	new[239]	_	_
29-12	5098-5107	condition	abstract[239]	new[239]	_	_
29-13	5108-5110	in	abstract[239]	new[239]	_	_
29-14	5111-5116	which	abstract[239]	new[239]	_	_
29-15	5117-5120	the	abstract[239]|abstract[240]	new[239]|new[240]	_	_
29-16	5121-5125	role	abstract[239]|abstract[240]	new[239]|new[240]	_	_
29-17	5126-5128	of	abstract[239]|abstract[240]	new[239]|new[240]	_	_
29-18	5129-5132	the	abstract[239]|abstract[240]|abstract[241]	new[239]|new[240]|giv[241]	_	_
29-19	5133-5143	microbiome	abstract[239]|abstract[240]|abstract[241]	new[239]|new[240]|giv[241]	_	_
29-20	5144-5147	has	abstract[239]	new[239]	_	_
29-21	5148-5156	emerging	abstract[239]	new[239]	_	_
29-22	5157-5159	as	abstract[239]	new[239]	_	_
29-23	5160-5163	one	abstract[239]|abstract[242]	new[239]|new[242]	_	_
29-24	5164-5166	of	abstract[239]|abstract[242]	new[239]|new[242]	_	_
29-25	5167-5170	the	abstract[239]|abstract[242]|abstract[243]	new[239]|new[242]|giv[243]	_	_
29-26	5171-5175	most	abstract[239]|abstract[242]|abstract[243]	new[239]|new[242]|giv[243]	_	_
29-27	5176-5185	important	abstract[239]|abstract[242]|abstract[243]	new[239]|new[242]|giv[243]	_	_
29-28	5186-5193	factors	abstract[239]|abstract[242]|abstract[243]	new[239]|new[242]|giv[243]	_	_
29-29	5194-5195	.	_	_	_	_

#Text=Several publications have reported a clear demonstration of the link between osteoarthritis and gut microbiota .
30-1	5196-5203	Several	organization[244]	new[244]	_	_
30-2	5204-5216	publications	organization[244]	new[244]	_	_
30-3	5217-5221	have	_	_	_	_
30-4	5222-5230	reported	_	_	_	_
30-5	5231-5232	a	event[245]	new[245]	_	_
30-6	5233-5238	clear	event[245]	new[245]	_	_
30-7	5239-5252	demonstration	event[245]	new[245]	_	_
30-8	5253-5255	of	event[245]	new[245]	_	_
30-9	5256-5259	the	event[245]|abstract[246]	new[245]|new[246]	_	_
30-10	5260-5264	link	event[245]|abstract[246]	new[245]|new[246]	_	_
30-11	5265-5272	between	event[245]|abstract[246]	new[245]|new[246]	_	_
30-12	5273-5287	osteoarthritis	event[245]|abstract[246]|abstract	new[245]|new[246]|new	coref	31-18
30-13	5288-5291	and	event[245]|abstract[246]	new[245]|new[246]	_	_
30-14	5292-5295	gut	event[245]|abstract[246]|abstract|abstract[249]	new[245]|new[246]|giv|giv[249]	_	_
30-15	5296-5306	microbiota	event[245]|abstract[246]|abstract[249]	new[245]|new[246]|giv[249]	_	_
30-16	5307-5308	.	_	_	_	_

#Text=For instance , animals with a low-grade chronic systemic inflammation due to a high-fat diet have developed osteoarthritis , and others with an increased body weight due to diet have shown an increased progression of osteoarthritis .
31-1	5309-5312	For	_	_	_	_
31-2	5313-5321	instance	_	_	_	_
31-3	5322-5323	,	_	_	_	_
31-4	5324-5331	animals	animal[250]	new[250]	_	_
31-5	5332-5336	with	animal[250]	new[250]	_	_
31-6	5337-5338	a	animal[250]|abstract[251]	new[250]|giv[251]	coref	32-22[268_251]
31-7	5339-5348	low-grade	animal[250]|abstract[251]	new[250]|giv[251]	_	_
31-8	5349-5356	chronic	animal[250]|abstract[251]	new[250]|giv[251]	_	_
31-9	5357-5365	systemic	animal[250]|abstract[251]	new[250]|giv[251]	_	_
31-10	5366-5378	inflammation	animal[250]|abstract[251]	new[250]|giv[251]	_	_
31-11	5379-5382	due	animal[250]|abstract[251]	new[250]|giv[251]	_	_
31-12	5383-5385	to	animal[250]|abstract[251]	new[250]|giv[251]	_	_
31-13	5386-5387	a	animal[250]|abstract[251]|event[252]	new[250]|giv[251]|giv[252]	coref	31-29[0_252]
31-14	5388-5396	high-fat	animal[250]|abstract[251]|event[252]	new[250]|giv[251]|giv[252]	_	_
31-15	5397-5401	diet	animal[250]|abstract[251]|event[252]	new[250]|giv[251]|giv[252]	_	_
31-16	5402-5406	have	_	_	_	_
31-17	5407-5416	developed	_	_	_	_
31-18	5417-5431	osteoarthritis	abstract	giv	coref	31-36
31-19	5432-5433	,	_	_	_	_
31-20	5434-5437	and	_	_	_	_
31-21	5438-5444	others	person[254]	new[254]	_	_
31-22	5445-5449	with	person[254]	new[254]	_	_
31-23	5450-5452	an	person[254]|abstract[256]	new[254]|new[256]	_	_
31-24	5453-5462	increased	person[254]|abstract[256]	new[254]|new[256]	_	_
31-25	5463-5467	body	person[254]|object|abstract[256]	new[254]|new|new[256]	_	_
31-26	5468-5474	weight	person[254]|abstract[256]	new[254]|new[256]	_	_
31-27	5475-5478	due	person[254]	new[254]	_	_
31-28	5479-5481	to	person[254]	new[254]	_	_
31-29	5482-5486	diet	person[254]|event	new[254]|giv	_	_
31-30	5487-5491	have	_	_	_	_
31-31	5492-5497	shown	_	_	_	_
31-32	5498-5500	an	event[258]	new[258]	_	_
31-33	5501-5510	increased	event[258]	new[258]	_	_
31-34	5511-5522	progression	event[258]	new[258]	_	_
31-35	5523-5525	of	event[258]	new[258]	_	_
31-36	5526-5540	osteoarthritis	event[258]|abstract	new[258]|giv	_	_
31-37	5541-5542	.	_	_	_	_

#Text=Metcalfe et al. proposed that metabolic endotoxemia ( raised LPS blood and synovial concentrations ) caused by impaired gastric mucosa and low-grade chronic inflammation , may contribute to the onset and progression of OA in obese patients .
32-1	5543-5551	Metcalfe	person	new	_	_
32-2	5552-5554	et	abstract	new	_	_
32-3	5555-5558	al.	_	_	_	_
32-4	5559-5567	proposed	_	_	_	_
32-5	5568-5572	that	_	_	_	_
32-6	5573-5582	metabolic	abstract[262]	new[262]	_	_
32-7	5583-5594	endotoxemia	abstract[262]	new[262]	_	_
32-8	5595-5596	(	animal[266]	giv[266]	_	_
32-9	5597-5603	raised	animal[266]	giv[266]	_	_
32-10	5604-5607	LPS	substance|animal[266]	new|giv[266]	_	_
32-11	5608-5613	blood	substance|animal[266]	new|giv[266]	_	_
32-12	5614-5617	and	animal[266]	giv[266]	_	_
32-13	5618-5626	synovial	substance|animal[266]	new|giv[266]	_	_
32-14	5627-5641	concentrations	animal[266]	giv[266]	_	_
32-15	5642-5643	)	animal[266]	giv[266]	_	_
32-16	5644-5650	caused	animal[266]	giv[266]	_	_
32-17	5651-5653	by	animal[266]	giv[266]	_	_
32-18	5654-5662	impaired	animal[266]|object[267]	giv[266]|new[267]	_	_
32-19	5663-5670	gastric	animal[266]|object[267]	giv[266]|new[267]	_	_
32-20	5671-5677	mucosa	animal[266]|object[267]	giv[266]|new[267]	_	_
32-21	5678-5681	and	animal[266]	giv[266]	_	_
32-22	5682-5691	low-grade	animal[266]|abstract[268]	giv[266]|giv[268]	_	_
32-23	5692-5699	chronic	animal[266]|abstract[268]	giv[266]|giv[268]	_	_
32-24	5700-5712	inflammation	animal[266]|abstract[268]	giv[266]|giv[268]	_	_
32-25	5713-5714	,	_	_	_	_
32-26	5715-5718	may	_	_	_	_
32-27	5719-5729	contribute	_	_	_	_
32-28	5730-5732	to	_	_	_	_
32-29	5733-5736	the	abstract[269]|abstract[270]	giv[269]|giv[270]	_	_
32-30	5737-5742	onset	abstract[269]|abstract[270]	giv[269]|giv[270]	_	_
32-31	5743-5746	and	abstract[270]	giv[270]	_	_
32-32	5747-5758	progression	abstract[270]|event[271]	giv[270]|new[271]	_	_
32-33	5759-5761	of	abstract[270]|event[271]	giv[270]|new[271]	_	_
32-34	5762-5764	OA	abstract[270]|event[271]|abstract	giv[270]|new[271]|giv	_	_
32-35	5765-5767	in	abstract[270]|event[271]	giv[270]|new[271]	_	_
32-36	5768-5773	obese	abstract[270]|event[271]|person[273]	giv[270]|new[271]|giv[273]	_	_
32-37	5774-5782	patients	abstract[270]|event[271]|person[273]	giv[270]|new[271]|giv[273]	_	_
32-38	5783-5784	.	_	_	_	_
